0.45Open0.50Pre Close10 Volume3.13K Open Interest13.00Strike Price450.00Turnover120.22%IV28.59%PremiumJan 17, 2025Expiry Date0.00Intrinsic Value100Multiplier21DDays to Expiry0.45Extrinsic Value100Contract SizeAmericanOptions Type0.2764Delta0.1100Gamma23.24Leverage Ratio-0.0242Theta0.0014Rho6.42Eff Leverage0.0085Vega
Omeros Stock Discussion
Omeros’ Narsoplimab Meets its Pivotal Trial Primary Endpoint – Statistical Analysis Shows Survival Superiority Over External Control in Patients with TA-TMA
Omeros (OMER) announced successful results from its narsoplimab pivotal trial for treating transplant-associated thrombotic microangiopathy (TA-TMA). The primary statistical analysis showed that patients treated with narsoplimab had an over 3-fold reduction in mortality risk (hazard ratio = 0.32) compared to untreated p...
No comment yet